PF-04691502
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for PF-04691502, covering 2012-10-29 to 2015-05-19. Get the full timeline:
Most recent: Clinical Trial Update: A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer [Phase 2]